By Kim Richters 
 

Sanofi and Translate Bio Inc. are starting the Phase 1/2 clinical trial of their mRNA Covid-19 vaccine candidate, the companies said Friday.

The clinical trial--expected with 415 participants--will assess safety, immune response and reactogenicity, and interim results are expected in the third quarter, Sanofi and Translate said.

Preclinical data for the candidate vaccine MRT5500 had demonstrated high neutralizing antibody levels, they said.

Sanofi and Translate said they are also working on improving the vaccine's temperature stability.

At the same time, pre-clinical studies are continuing to assess MRT5500 and additional mRNA vaccine candidates against SARS-CoV-2 variants, the companies said.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

March 12, 2021 01:46 ET (06:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Sanofi Charts.